Synthetic tuftsin-derived neuropeptide · Also known as TP-7, Selank heptapeptide
A synthetic anxiolytic peptide derived from the immunoregulatory peptide tuftsin, developed in Russia for anxiety and cognitive support. It modulates GABA, serotonin, and BDNF without the sedation or dependence associated with benzodiazepines.
Selank was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences and is approved in Russia as an anxiolytic. Its structure is based on tuftsin (an endogenous immunostimulatory peptide) with a Pro-Gly-Pro extension that increases metabolic stability. Clinical studies in Russia demonstrated anxiolytic effects comparable to low-dose benzodiazepines, without sedation, amnesia, withdrawal, or dependence. It also has immunomodulatory properties inherited from its tuftsin backbone.
Selank modulates GABAergic neurotransmission through allosteric modulation of GABA-A receptors, producing anxiolytic effects similar to benzodiazepines. This is supported by studies showing changes in the expression of genes involved in GABAergic signaling after administration.
Beyond GABA, Selank influences serotonin metabolism, increases BDNF expression in the hippocampus, and modulates dopaminergic pathways. Its tuftsin backbone also provides immunomodulatory effects, influencing the expression of interleukins and other immune mediators. This dual action on both the nervous and immune systems makes it unique among anxiolytic compounds.
150-250 mcg subcutaneous daily, or 400-600 mcg intranasal daily
Weeks 1-2250-300 mcg subcutaneous daily, or 600-900 mcg intranasal daily
14-day cyclesMost side effects tend to improve as your body adjusts.